Amarin seeks OK for new heart drug

Amarin has filed for an FDA approval of its fish-oil heart drug, AMR101. The small biotech hopes to win an approval to use the drug to treat patients with high levels of blood fat. And some analysts have pegged the treatment as a potential blockbuster. "This is another significant milestone achieved for Amarin," said Joseph S. Zakrzewski, chairman and chief executive of Amarin, in a statement. "The submission... moves AMR101 one step closer to commercial launch." Story

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.